Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 20 September 2022, 23:50 HKT/SGT
Share:
Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference

Gaithersburg, MD, USA and Suzhou BioBay, China, Sept 20, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead(TM) platform and programs, at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference. The conference will take place on September 21 and 22, 2022 with workshops on September 20, 2022 at Copthorne Tara Hotel, London, UK.

Presentation Details

Presentation Title: Delivery of Novel siRNA Constructs for Treating Cancer
Presenter: Dr. David Evans, Chief Scientific Officer, Sirnaomics
Time/Date: 15:20 GMT on Wednesday, September 21, 2022
Presentation Topics:
-- Creating novel siRNA constructs for cancer treatment
-- Introduction to Sirnaomics' polypeptide nanoparticle delivery system (PNP-IT)
-- Introduction to STP705, Sirnaomics' lead oncology siRNA therapeutic targeting TGF-beta1/COX-2
-- Discussion of novel siRNA therapeutics targeting other oncology indications

Presentation Title: GalAhead(TM) Therapeutic Platform and Programs
Presenter: Dr. Jack Wei, Senior Director, Sirnaomics
Time/Date: 16:30 GMT on Thursday, September 22, 2022
Presentation Topics:
-- Introduction to GalAhead(TM), Sirnaomics' GalNAc-RNAi therapeutic platform
-- Miniaturized RNAi (mxRNA) as a key technological component of the platform
-- Validation of technology in vivo and in vitro
-- Progress report on GalAhead(TM)-based programs

For more information about Sirnaomics' presentation, please visit the event website at https://www.smgconferences.com/pharmaceuticals/uk/conference/oligonucleotide-discovery-delivery.

About Sirnaomics

Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705. Learn more at www.sirnaomics.com.

CONTACT:
Investor Relations:
Nigel Yip, MBA
Chief Financial Officer, China, Sirnaomics
Email: NigelYip@sirnaomics.com

US Media Contact:
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com

Asia Media Contact:
Bunny Lee
Tel: +852 3150 6707
Email: sirnaomics.hk@pordahavas.com



Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation  
July 4, 2025 18:59 HKT/SGT
DENSO Acquires Axia Vegetable Seeds to Realize Sustainable Agriculture  
Friday, July 4, 2025 3:20:00 PM
MHIET Launches 450kW Gas Cogeneration System Capable of Hydrogen Co-Firing  
Friday, July 4, 2025 2:13:00 PM
INVEST FAIR Malaysia 2025 Spotlights Investor Trends, Multi-Asset Literacy, and Tech-Driven Platforms  
July 4, 2025 13:00 HKT/SGT
Yachiyo Engineering and NEC launch adaptation finance study in Indonesia to calculate the adaptation value of disaster prevention measures  
Friday, July 4, 2025 12:25:00 PM
Fujitsu to implement store monitoring solution for METRO Inc. in Canada, enhancing operational efficiency and policy compliance  
Friday, July 4, 2025 12:19:00 PM
Chinabank Fully Transitions Into AI-powered Human Capital Management  
July 3, 2025 20:30 HKT/SGT
UOB Hong Kong becomes first Singapore-based bank to sign MOU with HKTDC  
July 3, 2025 16:29 HKT/SGT
Fujitsu to develop ETF trading platform based on TSE's CONNEQTOR and provide it to Australian Securities Exchange  
Thursday, July 3, 2025 10:14:00 AM
AI-Powered CX, Operational Efficiency, and Smarter Journeys Redefining Strategies Across UK Enterprises: Customer Experience Live Show UK 2025 Unveils Industry Priorities  
July 3, 2025 08:59 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: